-4, IL-5, and IL-13 also improved inside the OVA+BPS-M Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEWOVA+BPS-H groups compared with the levels inside the OVA of 19 ten group (Figure 9b ). The and degree of IFN- also showed a related trend, but alterations were not statistically considerable (Figure 9e).Figure 8. Expression of cell number and cell surface molecules in MLNs. Cell surface molecule exFigure 8. Expression of cell quantity and cell surface molecules in MLNs. Cell surface molecule pression was determined via fluorescence-activated cell sorting evaluation 48 h immediately after the final OVA expression was determined cell fluorescence-activated cell sorting evaluation intratracheal administration. (a) Total vianumber. (b) Percentage of MHC class II+ CD86+ cells. (c) 48 h right after the final OVA Percentage of pDC. (d) Percentage of cDC. (e) Percentagenumber. total Percentage of MHC class II+ CD86+ cells. intratracheal administration. (a) Total cell of cDC1 in (b) cDC. (f) Percentage of cDC2 in total cDC. Information are expressed as indicates SE for 6 animals per group. p 0.05 vs. OVA (c) Percentage OVA group. cDC, standard dendritic cells; MLN, mediastinal lymph node; group, p 0.01 vs. of pDC. (d) Percentage of cDC. (e) Percentage of cDC1 in total cDC. (f) Percentage of OVA, ovalbumin; pDC, plasmacytoid dendritic cells; as suggests SE for 6 animals per group. p 0.05 vs. OVA cDC2 in total cDC. Data are expressed SE, common error.group, p 0.01 vs. OVA group. cDC, traditional dendritic cells; MLN, mediastinal lymph node; OVA, ovalbumin; pDC, plasmacytoid dendritic cells; SE, normal error.Int. J. Mol. Sci. 2022, 23, x FOR PEER Overview Int. J. Mol. Sci. 2022, 23,11 of 19 9 ofFigure 9. Activation of MLN cells. MLN cell proliferation and cytokine expression in the culture Figure 9. Activation of MLN cells. MLN cell proliferation and cytokine expression in the culture supernatant were analyzed 91 h soon after OVA restimulation.Oxelumab Purity & Documentation (a) Cell proliferation (Abs).Sennoside A Autophagy (b) (b) IL-4.IL-5. 91 h soon after OVA restimulation. (a) Cell proliferation (Abs). IL-4. (c) (c) supernatant had been IL-5.IL-13. (e) IFN-. Data areare expressed as imply SE of 6animals per group. p 0.05 vs. OVA (d) (d) IL-13.PMID:24428212 (e) IFN-. Data expressed as imply SE of six animals per group. p 0.05 vs. OVA group, pp0.01 vs. OVA group. IFN, interferon; IL, interleukin; MLN, mediastinal lymph node; group, 0.01 vs. OVA group. IFN, interferon; IL, interleukin; MLN, mediastinal lymph node; OVA, ovalbumin; SE, standard error. OVA, ovalbumin; SE, normal error.3. Discussion 3. Discussion This study investigated the effects of oral exposure to low doses of BPS (equivalent to oral exposure to low doses of BPS (equivalent This study investigated to doses of 0.04, 0.4, and 4 g/kg/day) allergic asthmatic mice. Compared with with OVA doses of 0.04, 0.4, and 4 /kg/day) in in allergic asthmatic mice. Compared OVA alone, BPS-M and BPS-H with with enhanced allergic pulmonary inflammation, Th2 Th2 cyalone, BPS-M and BPS-H OVA OVA enhanced allergic pulmonary inflammation, cytokine and chemokine production, and serum serum OVA-specific Ig Also, addition, tokine and chemokine production, andOVA-specific Ig secretion.secretion. In MLN cells were activated activated following BPS exposure in OVA-sensitized mice. Notably, these MLN cells werefollowing BPS exposure in OVA-sensitized mice. Notably, these final results were additional were more remarkable inside the OVA+BPS-M group than within the group. Though the resultsremarkable within the OVA+BPS-M group than in th.